AAM sends letters to House on HR 987The Association for Accessible Medicines has sent two letters to Capital Hill in advance of House consideration of H.R. 987. Mylan launches generic TarcevaErlotinib hydrochloride tablets have a market value of roughly $212 million. Amerigen's generic Cuprimine gets FDA OK The Food and Drug Administration approved Cuprimine's penicillamine capsules. Teva launches generic Delzicol Delzicol delayed-release capsules have a market value of roughly $130 million, according to February 2019 IQVIA data. Lupin launches generic Onfi Clobazam tablets have a market value of roughly $479 million, according to March 2019 IQVIA data. Gilead’s Truvada to see generic launch in September 2020 Teva is expected to launch its generic of Gilead's Truvada one year earlier than expected. Teva launches generic Tarceva Tarceva tablets have a market value of $202 million, according to IQVIA data as of February 2019. AAM, Biosimilars Council oppose FDA biosimilar naming update The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars. FDA gives tentative nod for Lupin's generic Emend Fosaprepitant for injection, 150 mg single-dose vial, had a market value of approximately $312 million for the year ended March 2019, per IQVIA data. Teva launches generic Letairis Letairis had a market value of roughly $247 million as of February 2019, according to IQVIA data. First Previous 172 173 174 175 176 Next Last